Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol

The newly synthesized 188Re-HDD/lipiodol showed improved radiolabeling yield and biodistribution results compared to 188Re-HTDD/lipiodol, and may therefore be more suitable for liver cancer therapy.